PRSS3 promotes tumour growth and metastasis of human pancreatic cancer

Gut

Volumn 59, Issue 11, 2010, Pages 1535-1544

  Jiang, Guozhong ^a,b   Cao, Fengyu ^a   Ren, Guoping ^c   Gao, Dongling ^a   Bhakta, Vipul ^b   Zhang, Yunhan ^a   Cao, Hua ^a   Dong, Ziming ^a   Zang, Weidong ^a   Zhang, Shuijun ^a   Wong, Han Hsi ^b   Hiley, Crispin ^b   Crnogorac Jurcevic, Tatjana ^b   Lemoine, Nick R ^a,b   Wang, Yaohe ^a,b  

^a ZHENGZHOU UNIVERSITY   (China)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEIN PRSS3; PROTEINASE ACTIVATED RECEPTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN; 1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ENZYME INHIBITOR; NITRILE; PRSS3 PROTEIN, HUMAN; TRYPSIN; TUMOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; PANCREAS CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; SURVIVAL TIME; UPREGULATION; ANIMAL; CANCER TRANSPLANTATION; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; METABOLISM; MIDDLE AGED; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY; SURVIVAL; TUMOR CELL CULTURE;

ADULT; AGED; ANIMALS; BUTADIENES; CELL PROLIFERATION; DISEASE PROGRESSION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NITRILES; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; TRYPSIN; TUMOR CELLS, CULTURED; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78049498605     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.200105     Document Type: Article

References (36)

1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2008;58:71-96.
3. Sperti C, Pasquali C, Piccoli A, et al. Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg 1996;83:625-31.
4. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin 2006;56:106-30.
5. Mao C, Domenico DR, Kim K, et al. Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg 1995;130:125-34.
6. Hermanek P. Pathology and biology of pancreatic ductal adenocarcinoma. Langenbecks Arch Surg 1998;383:116-20.
7. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.
8. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-18.
9. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795-803.
10. Seo Y, Baba H, Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000;88:2239-45.
11. Yachida S, Iacobuzio-Donahue CA. The pathology and genetics of metastatic pancreatic cancer. Arch Pathol Lab Med 2009;133:413-22.
12. Kleeff J, Michalski C, Friess H, et al. Pancreatic cancer: from bench to 5-year survival. Pancreas 2006;33:111-18.
13. Campagna D, Cope L, Lakkur SS, et al. Gene expression profiles associated with advanced pancreatic cancer. Int J Clin Exp Pathol 2008;1:32-43.
14. Elsasser HP, Lehr U, Agricola B, et al. Establishment and characterisation of two cell lines with different grade of differentiation derived from one primary human pancreatic adenocarcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol 1992;61:295-306.
15. Wang Y, Gangeswaran R, Zhao X, et al. CEACAM6 attenuates adenovirus infection by antagonizing viral trafficking in cancer cells. J Clin Invest 2009;119:1604-15.
16. Boire A, Covic L, Agarwal A, et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005;120:303-13.
17. Wang Y, Luo W, Wartmann T, et al. Mesotrypsin, a brain trypsin, activates selectively proteinase-activated receptor-1, but not proteinase-activated receptor-2, in rat astrocytes. J Neurochem 2006;99:759-69.
18. Cottrell GS, Amadesi S, Grady EF, et al. A novel agonist of protease-activated receptors 2 and 4. J Biol Chem 2004;279:13532-9.
19. Grishina Z, Ostrowska E, Halangk W, et al. Activity of recombinant trypsin isoforms on human proteinase-activated receptors (PAR): mesotrypsin cannot activate epithelial PAR-1, -2, but weakly activates brain PAR-1. Br J Pharmacol 2005;146:990-9.
20. Knecht W, Cottrell GS, Amadesi S, et al. Trypsin IV or mesotrypsin and p23 cleave protease-activated receptors 1 and 2 to induce inflammation and hyperalgesia. J Biol Chem 2007;282:26089-100.
21. O'Brien PJ, Prevost N, Molino M, et al. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J Biol Chem 2000;275:13502-9.
22. Darmoul D, Gratio V, Devaud H, et al. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol 2003:1503-13.
23. Emi M, Nakamura Y, Ogawa M, et al. Cloning, characterization and nucleotide sequences of two cDNAs encoding human pancreatic trypsinogens. Gene 1986;41:305-10.
24. Tani T, Kawashima I, Mita K, et al. Nucleotide sequence of the human pancreatic trypsinogen III cDNA. Nucleic Acids Res 1990;18:1631.
25. Wiegand U, Corbach S, Minn A, et al. Cloning of the cDNA encoding human brain trypsinogen and characterization of its product. Gene 1993;136:167-75.
26. Rinderknecht H, Renner IG, Abramson SB, et al. Mesotrypsin: a new inhibitor-resistant protease from a zymogen in human pancreatic tissue and fluid. Gastroenterology 1984;86:681-92.
27. Szmola R, Kukor Z, Sahin-Toth M. Human mesotrypsin is a unique digestive protease specialized for the degradation of trypsin inhibitors. J Biol Chem 2003;278:48580-9.
28. Diederichs S, Bulk E, Steffen B, et al. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res 2004;64:5564-9.
29. Marsit CJ, Karagas MR, Danaee H, et al. Carcinogen exposure and gene promoter hypermethylation in bladder cancer. Carcinogenesis 2006;27:112-16.
30. Marsit CJ, Okpukpara C, Danaee H, et al. Epigenetic silencing of the PRSS3 putative tumor suppressor gene in non-small cell lung cancer. Mol Carcinog 2005;44:146-50.
31. Yamashita K, Mimori K, Inoue H, et al. A tumor-suppressive role for trypsin in human cancer progression. Cancer Res 2003;63:6575-8.
32. Nyaruhucha CN, Kito M, Fukuoka SI. Identification and expression of the cDNA-encoding human mesotrypsin(ogen), an isoform of trypsin with inhibitor resistance. J Biol Chem 1997;272:10573-8.
33. Katona G, Berglund GI, Hajdu J, et al. Crystal structure reveals basis for the inhibitor resistance of human brain trypsin. J Mol Biol 2002;315:1209-18.
34. Herszenyi L, Istvan G, Cardin R, et al. Serum cathepsin B and plasma urokinase-type plasminogen activator levels in gastrointestinal tract cancers. Eur J Cancer Prev 2008;17:438-45.
35. Niedergethmann M, Wostbrock B, Sturm JW, et al. Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma. Pancreas 2004;29:204-11.
36. Tzanakakis GN, Margioris AN, Tsatsakis AM, et al. The metastatic potential of human pancreatic cell lines in the liver of nude mice correlates well with cathepsin B activity. Int J Gastrointest Cancer 2003;34:27-38.